Sign in Get started

Endocrinology, Diabetes and Metabolism

Filters3 filters applied

Status

Corrected
No notice
From publisher notices and Retraction Watch. Not checked means nobody has looked yet.

Year

Readable here

Study type

Licence

CC BY

10 papers9 with full text Questions on this topic

2 filters appliedStatus: No notice Study type: Randomised trial Clear all

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Naveed Sattar, David Fitchett, Stefan Hantel et al. · Diabetologia · 2018 · Randomised trial
Full textCC BY
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
on behalf of the DEVOTE Study Group, Bernard Zinman, Steven P. Marso et al. · Diabetologia · 2017 · Randomised trial
Full textCC BY
Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial
Julia K Prague, Rachel E Roberts, Alexander N Comninos et al. · The Lancet · 2017 · Randomised trial
Full textCC BY
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu et al. · Circulation · 2017 · Randomised trial
Full textCC BY
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Mark M. Smits, Lennart Tonneijck, Marcel H. A. Muskiet et al. · Diabetologia · 2016 · Randomised trial
Full textCC BY
Effects of 2‐year calorie restriction on circulating levels of IGF‐1, IGF‐binding proteins and cortisol in nonobese men and women: a randomized clinical trial
Luigi Fontana, Dennis T. Villareal, Sai K. Das et al. · Aging Cell · 2015 · Randomised trial
Full textCC BY
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Bernard Zinman, Silvio E Inzucchi, John M Lachin et al. · Cardiovascular Diabetology · 2014 · Randomised trial
Full textCC BY
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J.‐F. Yale, G. Bakris, B. Cariou et al. · Diabetes, Obesity and Metabolism · 2013 · Randomised trial
Abstract only
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
R. Pratley, M. Nauck, T. Bailey et al. · International Journal of Clinical Practice · 2011 · Randomised trial
Full textCC BY
The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome
Mathieu Firmann, Vladimir Mayor, Pedro Marques Vidal et al. · BMC Cardiovascular Disorders · 2008 · Randomised trial
Full textCC BY